The purpose of this research is to determine how well patients respond to this combination treatment over a 12-month period. The medications work in different ways to target and destroy cancer cells – loncastuximab tesirine is an antibody-drug combination that delivers medication directly to cancer cells, while epcoritamab is a specialized antibody that helps the immune system recognize and fight cancer cells.

During the study, participants will receive both medications according to a specific schedule. Patients will have regular check-ups and imaging tests to monitor how their cancer responds to the treatment. The treatment period may last up to 54 weeks, depending on how well the patient responds and tolerates the medications. Throughout the study, doctors will closely monitor patients for any side effects or complications from the treatment.

The study will test if taking dapagliflozin while receiving standard lymphoma treatment can help prevent heart-related side effects. Participants will receive either dapagliflozin or placebo tablets for 6 months while undergoing their regular cancer treatment. The medication or placebo will be taken by mouth once daily.

During the study, doctors will monitor heart function using various tests to measure how well the heart is working. These tests include examining heart muscle movement, blood flow patterns, and checking certain substances in the blood that can indicate heart health. The study will also track any heart-related symptoms that participants may experience during their treatment.

The purpose of the study is to see how well these treatments work in achieving a complete response, which means the disappearance of all signs of cancer in response to treatment. Participants will receive the treatments through intravenous infusions, which means the medication is given directly into a vein, and some medications will be taken orally. The study will monitor participants over a period to assess the effectiveness of the treatments and any side effects that may occur.

Throughout the study, participants will be closely observed to track their health and any changes in their condition. The study aims to provide valuable information on the potential benefits and risks of these treatment combinations for people with this specific type of lymphoma. The ultimate goal is to improve treatment options and outcomes for individuals diagnosed with Diffuse Large B-Cell Lymphoma.

The purpose of the study is to evaluate how well these treatments work together in patients whose lymphoma has returned or has not responded to previous treatments. Loncastuximab Tesirine is an antibody-drug conjugate, which means it is designed to deliver a drug directly to cancer cells, while Epcoritamab is a bispecific antibody that helps the immune system target and destroy cancer cells. The study will involve administering these treatments to participants and monitoring their response over a period of time, up to 12 months, to see if the cancer shrinks or disappears.

Participants in the study will receive the treatments through injections, with Loncastuximab Tesirine given intravenously (through a vein) and Epcoritamab given subcutaneously (under the skin). The study aims to determine the best overall response rate, which includes both complete and partial remissions, and will also look at other outcomes such as progression-free survival and overall survival. The study will help researchers understand the potential benefits and risks of this combination therapy for patients with these types of lymphoma.

The purpose of the study is to assess how effective Epcoritamab is when used alongside Lenalidomide and Rituximab in treating this specific type of lymphoma. Participants in the study will receive these medications over a series of treatment cycles. The study will monitor the response of the cancer to the treatment during the initial phase, which consists of eight cycles. The goal is to determine the best response rate, which includes complete or partial reduction of the cancer, as recommended by international guidelines for this type of lymphoma.

Throughout the study, participants will undergo regular assessments, including imaging tests like MRI (Magnetic Resonance Imaging), to evaluate the progress of the treatment. The study aims to provide valuable information on the effectiveness of this treatment combination, which could potentially lead to improved outcomes for patients with this challenging form of lymphoma.

The purpose of the study is to see if the new combination of treatments can help people with DLBCL live longer without their disease getting worse. Participants in the study will receive either the new treatment combination or the standard treatment. The study will last for up to 18 months, during which participants will receive their assigned treatment and be monitored regularly. The study will also look at how the treatments affect participants’ quality of life and any side effects they may experience.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the progress of their disease. These tests may include imaging scans and blood tests. The study aims to provide valuable information about the effectiveness and safety of the new treatment combination for people with DLBCL.

The study is testing a new treatment called CD19-CAR_Lenti, which involves using the patient’s own immune cells, called T-cells, that are modified in the lab to better recognize and attack cancer cells. This treatment is given through an infusion into the bloodstream. In addition to CD19-CAR_Lenti, the study also uses two other medications, Fludarabine Phosphate and Cyclophosphamide, which are types of chemotherapy drugs that help prepare the body to receive the modified T-cells.

The purpose of the study is to find out how safe and effective the CD19-CAR_Lenti treatment is for these types of cancer. Participants will receive the treatment and be monitored over time to see how their cancer responds. The study will look at how well the treatment works in reducing cancer cells and how long the effects last. Participants will have regular check-ups and tests to track their progress and any side effects they might experience. The study aims to determine the best dose of the treatment and to see if it can help achieve remission, which means the cancer is no longer detectable in the body.

The purpose of the study is to determine how safe and tolerable AZD0486 is when given to patients with these types of blood cancers. The study will also find the best dose to use in future research. Participants will receive the treatment either through an infusion into a vein or an injection under the skin. The study will be conducted in several phases, starting with a smaller group of participants to assess safety, and then expanding to include more participants to further evaluate the treatment’s effectiveness.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The trial aims to provide valuable information on how well AZD0486 works in treating these blood cancers and to ensure that it is safe for patients. The study is expected to continue until 2026, with recruitment starting in 2025.

Participants in the study will receive the treatment over a period of time, with Rituximab being administered intravenously, meaning it is given through a vein, and Golcadomide taken orally in capsule form. The study aims to provide a chemo-free approach, which means it does not involve traditional chemotherapy drugs. The trial will monitor the participants’ health and response to the treatment, focusing on how long they live without the disease getting worse, their overall response to the treatment, and any changes in their quality of life.

This study is particularly aimed at older patients who are not suitable for more aggressive treatments due to their frail condition. The trial will use a simplified geriatric assessment to determine the frailty of the participants. The study will continue for several years to gather comprehensive data on the effectiveness and safety of the treatment combination. Participants will be closely monitored throughout the study to ensure their well-being and to assess the outcomes of the treatment.

The trial involves several medications, including Cytarabine, Tafasitamab (also known as MOR00208), Lenalidomide, Dexamethasone, Cisplatin, Bendamustine Hydrochloride, Polatuzumab Vedotin (also known as RO5541077), and Rituximab. These medications are used in various forms such as solutions for infusion, injections, and capsules. Some patients may receive a placebo as part of the study. The study will monitor the overall response rate to the second-line treatment and any significant side effects that may occur.

Participants in the study will undergo regular assessments, including blood tests to measure circulating tumor DNA and imaging tests like PET-CT scans to monitor disease progression. The study will also evaluate the quality of life of participants using a specific questionnaire. The trial is expected to continue until early 2026, with the goal of improving treatment strategies for patients with these types of lymphomas.

Participants in the study will first receive the combination of Ibrutinib and Rituximab-CHOP. After this initial treatment phase, they will continue with Ibrutinib alone as a maintenance therapy. The study aims to observe the progression-free survival, which means the length of time during and after the treatment that the patient lives with the disease without it getting worse. Other aspects being monitored include overall survival, the rate of complete response, and any side effects or adverse events that may occur during the treatment.

This trial is designed to provide valuable information on the potential benefits and risks of using Ibrutinib in combination with Rituximab-CHOP for treating patients with ABC-DLBCL. The study will help determine if this treatment approach can improve outcomes for patients with this specific type of lymphoma. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatment.

The purpose of the study is to find the best dose of Rapcabtagene Autoleucel and to understand its safety and effectiveness in treating these cancers. The study is divided into two phases. In the first phase, researchers aim to determine the appropriate dose and assess the safety of the treatment, both alone and in combination with Ibrutinib for CLL/SLL. The second phase focuses on evaluating how well the treatment works in reducing or eliminating the cancer. Participants will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study will also look at how the treatment affects the cancer over time. This research is important for developing new ways to treat these types of blood cancers and could lead to more effective therapies in the future.

The purpose of the study is to test the safety and feasibility of using CLIC-1901 CAR T-cell therapy in patients whose cancer has returned or has not responded to previous treatments. Participants in the study will receive the treatment through an intravenous infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor the effects of the treatment over a period of time to understand how well it works and to identify any side effects. The trial will also look at how the treatment affects the overall health and survival of the participants.

Throughout the study, researchers will keep track of various health indicators, such as the response of the cancer to the treatment, any side effects experienced, and the overall survival of the participants. The study aims to provide valuable information on the potential benefits and risks of using CAR T-cell therapy in treating these types of blood cancers. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

Participants in this study will continue taking ibrutinib in the form of a hard capsule, which is taken orally. The study will monitor the long-term effects of ibrutinib and any potential side effects that may arise. Patients will be observed for any serious adverse events, which are significant health issues that may occur during the treatment. The study aims to ensure that patients who benefit from ibrutinib can maintain their treatment regimen and continue to manage their condition effectively.

The medications being tested in this trial include CYTARABINE, PROCARBAZINE, THIOTEPA, BUSULFAN, RITUXIMAB, and METHOTREXATE DISODIUM. These drugs are used in different forms, such as solutions for infusion or capsules, and are administered either intravenously or orally. The trial will also involve a placebo group to help determine the effectiveness of the treatments. The purpose of the study is to see if the intensified chemotherapy followed by HCT-ASCT is more effective than the conventional R-MP chemotherapy in terms of how long patients live without the disease getting worse.

Participants in the study will receive one of the two treatment plans and will be monitored over time to assess their quality of life, the remission of the disease, and any side effects they may experience. The study will also look at overall survival rates and any treatment-related issues, such as neurotoxicity, which refers to damage to the nervous system. The trial is expected to continue for several years, with the goal of providing valuable information on the best treatment options for elderly patients with PCNSL.

The purpose of this study is to determine if the combination of Epcoritamab and Lenalidomide can improve the time patients live without their disease getting worse, compared to the combination of Rituximab, Gemcitabine, and Oxaliplatin. Participants will be randomly assigned to one of the two treatment groups. The study will involve regular visits to the clinic for treatment and monitoring, which will include various tests and assessments to track the progress of the disease and the effects of the treatment.

Throughout the study, participants will receive either the active treatment or a placebo, depending on the group they are assigned to. The trial will continue for a set period, during which the health and response to treatment of the participants will be closely monitored by the medical team. The study aims to provide valuable information that could lead to better treatment options for patients with relapsed or refractory DLBCL.

The purpose of the study is to evaluate the safety and effectiveness of Tolinapant in treating these advanced cancers. Participants in the study will receive the medication in the form of a capsule taken by mouth. The study will be conducted in phases, with the first phase already completed. The second phase will focus on assessing how well the medication works in reducing the size of tumors or slowing their growth. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Tolinapant.

Throughout the study, participants will be monitored for any side effects and changes in their condition. The study aims to determine the best dose of Tolinapant and to gather information on how the body processes the medication. This information will help researchers understand the potential benefits and risks of using Tolinapant as a treatment for advanced cancers. The study is expected to continue until the end of 2025.

The purpose of the study is to evaluate the safety and effectiveness of this treatment combination. The study will observe how patients respond to the treatment over a period of time, specifically looking at how long patients remain free from disease progression. The treatment is administered through intravenous use, meaning it is given directly into a vein. The study will last for a maximum of 18 months, during which patients will receive regular doses of the medications.

Participants in the study will be monitored closely to assess any side effects and to determine the best dose of the new medication, copanlisib, when used with the R-CHOP regimen. The study aims to provide valuable information on the potential benefits and risks of this treatment combination for patients with DLBCL.

The purpose of this study is to evaluate how safe and effective this new treatment is for patients whose cancer has returned or has not responded to previous treatments. The study will be conducted in two phases. In the first phase, researchers will determine the best dose of MB-CART19.1 to use. In the second phase, they will assess how well the treatment works in reducing cancer cells in the body. Throughout the study, participants will receive the treatment and be monitored for any side effects and improvements in their condition.

Participants will receive the MB-CART19.1 treatment through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study aims to find out if this approach can help control or eliminate the cancer, and how long any positive effects might last. The trial will also look at the overall health and survival of participants over time. Some participants may receive a placebo as part of the study to help compare the effects of the treatment. The study is expected to continue until the end of 2025.

The trial will investigate a new medication called Golcadomide (also known by its code name CC-99282), which is taken orally in capsule form. This medication will be tested both on its own and in combination with other treatments for NHL, including Rituximab, Obinutuzumab, Tafasitamab, and Valemetostat Tosylate. Rituximab is a monoclonal antibody, which is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. The purpose of the study is to determine the safety and tolerability of Golcadomide alone and in combination with these other treatments, as well as to find the best dose to use in future studies.

Participants in the study will receive the medication and be monitored for any side effects or changes in their condition. The study will also look at how the body processes the medication and its preliminary effectiveness in treating the disease. The trial is designed to gather important information that could lead to new treatment options for people with relapsed or refractory NHL.

Participants in the study will receive the treatment over several cycles. Each cycle involves taking the medications in a specific order and at specific times. The study will monitor how the body responds to the treatment and any side effects that may occur. The goal is to see if the treatment can lead to a complete response, meaning the cancer is no longer detectable at the end of the treatment period.

The study is divided into two phases. The first phase aims to find the most effective dose of Tazemetostat, while the second phase focuses on evaluating the treatment’s success in achieving a complete response in patients. The study will continue until the end of 2026, with the hope of providing valuable information on improving treatment options for patients with DLBCL and FL.

The purpose of the study is to evaluate how well the new combination of Polatuzumab Vedotin, Rituximab, and CHP works in treating patients who have not received any prior treatment for their DLBCL. The study will also assess the safety of this treatment. Participants in the trial will receive their assigned treatment and will be monitored over a period of time to see how their disease responds. The study will involve regular check-ups and assessments to track the progress of the disease and any side effects from the treatment.

Throughout the study, participants will receive their treatments through intravenous (IV) infusions, which means the medication will be given directly into a vein. The trial aims to determine if the new treatment combination can improve outcomes for patients with DLBCL compared to the standard R-CHOP regimen. The study will help researchers understand if the new combination can help patients live longer without their disease getting worse.

The purpose of this research is to determine the best dose and effectiveness of combining Brentuximab Vedotin with R-DHAP chemotherapy as a second-line treatment. The study is divided into two parts. The first part will establish the appropriate dose of the medication combination, while the second part will evaluate how well the treatment works.

During the study, participants will receive Brentuximab Vedotin through intravenous administration along with R-DHAP chemotherapy. The treatment will be given in cycles, and patients who respond well to the treatment may proceed to receive high-dose chemotherapy followed by autologous stem cell transplantation (a procedure where a patient’s own stem cells are used for treatment). The total treatment period may last up to 9 months.

Participants in the study will receive a pre-treatment phase with oral prednisone, with some also receiving Vitamin D supplementation. This will be followed by six cycles of a standard cancer treatment called immunochemotherapy. The study is designed to compare the outcomes of those who receive Vitamin D with those who do not, to determine if the addition of Vitamin D provides any benefits in managing the disease.

The trial is open-label, meaning both the researchers and participants know which treatments are being administered. It is a randomized study, so participants will be randomly assigned to either receive Vitamin D with prednisone or prednisone alone. The study aims to provide valuable information on whether Vitamin D can enhance the effectiveness of the treatment for elderly patients with DLBCL and FL3B.

The purpose of the study is to explore how a protein called PD-L1 is expressed in both normal tissues and cancerous areas before patients receive CAR T-cell therapy. This will be done using a special imaging method called PET/CT scan, which combines two types of scans to provide detailed pictures of the inside of the body. The study aims to see if the amount of 89Zr-atezolizumab taken up by the body can help distinguish between active cancer and other treatment-related changes.

Participants in the study will undergo PET/CT imaging before and after receiving CAR T-cell therapy. The study will also look at how the uptake of 89Zr-atezolizumab relates to the effectiveness of the CAR T-cell therapy and any side effects that may occur. This research hopes to provide insights into the role of PD-L1 in DLBCL and improve understanding of how patients respond to CAR T-cell therapy.

The purpose of the study is to determine if adding Polatuzumab vedotin to the R-ICE regimen improves the time patients remain free from cancer events, which is referred to as event-free survival. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will follow participants over a period to monitor their response to the treatment and any side effects they may experience.

Throughout the study, researchers will collect information on various outcomes, such as how long patients remain free from cancer progression, the overall response to the treatment, and any side effects. The study will also look at the quality of life of participants during and after treatment. This research is important for understanding whether the addition of Polatuzumab vedotin can provide better outcomes for patients with relapsed or refractory DLBCL compared to the standard R-ICE treatment alone.

The purpose of the study is to evaluate how well the combination of Loncastuximab Tesirine and Rituximab works compared to the usual treatment for patients whose DLBCL has returned after treatment or has not responded to previous treatments. The study will involve participants receiving these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over a period of time, with regular monitoring to assess the progress and any effects of the treatment.

Participants in the study will be randomly assigned to receive either the new treatment combination or the standard treatment. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study aims to provide valuable information on whether the new treatment combination can improve outcomes for patients with relapsed or refractory DLBCL.

The purpose of the study is to evaluate the safety and how the body processes these medications when used together. Participants will receive a modified dosing schedule of tafasitamab, either once every two weeks or once every four weeks, combined with lenalidomide. The study will monitor the participants over a period to observe any side effects and to determine the most suitable dose of tafasitamab when used with lenalidomide.

Throughout the study, participants will be closely observed to track the occurrence and severity of any treatment-related side effects. Additionally, the study will assess how well the combination of tafasitamab and lenalidomide works in controlling the disease. This includes measuring the response of the cancer to the treatment and how long any positive effects last. The study aims to provide valuable information that could help improve treatment options for patients with relapsed or refractory DLBCL.

The purpose of this study is to estimate how well Golcadomide works when administered after the CAR T-cell therapy. Participants in the study will receive the CAR T-cell therapy first, which involves an infusion of modified immune cells. After this, they will be given Golcadomide in capsule form. Some participants may receive a placebo instead of Golcadomide. The study will monitor the participants over a period to see how their cancer responds to the treatment and to assess any side effects.

The trial will last for several years, with the estimated end date being in 2027. During the study, researchers will look at various outcomes, such as the rate of complete response to the treatment, how long the response lasts, and overall survival rates. This information will help determine the potential benefits of using Golcadomide after CAR T-cell therapy in patients with aggressive large B-cell lymphoma.

The purpose of this study is to determine if adding Epcoritamab to the standard R-CHOP treatment can help patients with newly diagnosed DLBCL live longer without their disease getting worse. Participants in the study will receive either the combination of Epcoritamab and R-CHOP or just R-CHOP. The study will involve several cycles of treatment, with Epcoritamab being given as a subcutaneous injection (an injection under the skin) and the R-CHOP medicines being given as intravenous infusions (medicines delivered directly into a vein).

The study will last for a period of time, during which participants will be monitored for any changes in their health and the progression of their disease. The goal is to see if the new treatment combination can improve the time patients live without their disease worsening, compared to the standard treatment alone. This study is important for understanding how to better treat DLBCL and potentially improve outcomes for patients with this type of cancer.

The study will involve participants receiving either the new treatment combination or the standard treatment. Some participants will receive a placebo instead of the new drugs to help compare the results. The trial will monitor the participants over a period to see how well the cancer responds to the treatments and to check for any side effects. The goal is to determine if the new combination of tafasitamab and lenalidomide with R-CHOP is more effective than R-CHOP alone in treating DLBCL.

Participants in the trial will undergo regular assessments to track their health and the progress of their treatment. These assessments will include various tests and evaluations to ensure the safety and effectiveness of the treatment. The study is expected to continue until 2026, providing valuable information on the potential benefits of the new treatment combination for patients with DLBCL.

The purpose of the study is to determine if Dexrazoxane can effectively prevent heart damage in patients receiving these treatments. Participants will be randomly assigned to receive either Dexrazoxane or a placebo, in addition to their standard cancer treatment. The study will monitor the participants’ heart health and overall response to the cancer treatment over a period of time. This will include regular check-ups and tests to assess heart function and the effectiveness of the cancer treatment.

The study will last for a period of approximately 126 days, with follow-up assessments to evaluate the long-term effects on heart health and cancer progression. The goal is to improve the safety and effectiveness of cancer treatments for patients with Diffuse Large B-Cell Lymphoma by reducing the risk of heart-related side effects. Participants will be closely monitored throughout the study to ensure their safety and well-being.

Participants in the study will receive the treatment through an intravenous (IV) infusion, which means the medication is given directly into a vein. The study will monitor the participants over a period to see how well the cancer responds to the treatment and to check for any side effects. The goal is to see if the combination of Glofitamab and R-CHOP can improve the complete response rate, which means the cancer is no longer detectable at the end of the treatment. The study will also look at other outcomes, such as overall survival and progression-free survival, which measures how long patients live without the cancer getting worse.

This trial is important because it explores a new potential treatment option for people with high-risk DLBCL, aiming to improve their chances of recovery and manage the disease more effectively. The study will provide valuable information on the safety and effectiveness of using Glofitamab in combination with R-CHOP, potentially leading to better treatment strategies for this type of lymphoma.

Participants in the study will be randomly assigned to receive either the combination of Acalabrutinib and R-CHOP or R-CHOP with a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The treatment will be administered over a period of several months, with regular follow-up visits to monitor the participants’ health and response to the treatment.

The study aims to provide valuable information on whether the addition of Acalabrutinib can enhance the effectiveness of the standard R-CHOP treatment for patients with previously untreated non-GCB DLBCL. By participating in this study, researchers hope to gather data that could lead to improved treatment options for this type of lymphoma in the future.

Participants in the study will receive either tisagenlecleucel or one of the standard care treatments, which may include medications such as fludarabine, ifosfamide, cisplatin, melphalan, oxaliplatin, carmustine, ibrutinib, lenalidomide, gemcitabine hydrochloride, rituximab, cyclophosphamide, bendamustine hydrochloride, tocilizumab, cytarabine, dexamethasone acetate, etoposide, or carboplatin. Some participants may receive a placebo. The purpose of the study is to see if tisagenlecleucel can delay the progression of the disease or improve survival compared to the standard treatments.

The study will involve regular assessments to monitor the participants’ health and the effectiveness of the treatment. These assessments will include medical tests and evaluations to track the progression of the lymphoma and any side effects of the treatments. The study is expected to continue until 2026, with participants being closely monitored throughout the trial period to ensure their safety and to gather comprehensive data on the treatment’s impact.

The purpose of the study is to evaluate how well Odronextamab works in shrinking tumors and to assess its safety in patients. The study includes several subtypes of B-cell non-Hodgkin lymphoma, such as follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma. Patients participating in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the patients over a period of time to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, researchers will collect information on how the cancer responds to Odronextamab and any changes in the patients’ health. This information will help determine the effectiveness of the treatment and its potential as a new option for patients with B-cell non-Hodgkin lymphoma. The study aims to provide valuable insights into the treatment of this type of cancer and improve future care for patients. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

Participants in the study will receive either the new treatment with Golcadomide or a placebo, along with the R-CHOP chemotherapy. The study will monitor the participants over a period to see how the cancer progresses and to check for any side effects. The main goal is to measure the time it takes for the cancer to worsen or for the patient to pass away, known as Progression-Free Survival (PFS). Other aspects being evaluated include overall survival, which is the time until death from any cause, and whether the cancer completely responds to the treatment.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the new treatment or the placebo. This helps ensure the results are unbiased. The trial will continue until 2029, with recruitment starting in 2024. The findings from this study could provide valuable insights into the treatment of High-risk Large B-cell Lymphoma and potentially improve outcomes for patients with this type of cancer.

Participants in the study will receive either odronextamab or one of the standard treatments, which may include medications like cisplatin, gemcitabine, carboplatin, dexamethasone, cytarabine, rituximab, etoposide, or ifosfamide. These treatments are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The study will last for several months, during which participants will be closely monitored by healthcare professionals to assess how well the treatments are working and to check for any side effects.

The main goal of the study is to see how long participants can live without their cancer getting worse, which is known as event-free survival. Other aspects being studied include how long participants live overall, how their quality of life changes, and how their bodies respond to the treatments. This information will help researchers understand if odronextamab could be a better option for treating aggressive B-cell non-Hodgkin’s lymphoma compared to the current standard treatments.

The purpose of the study is to assess how well Glofitamab works in treating these lymphomas after patients have already received a type of therapy known as CAR T-cell therapy. This therapy involves modifying a patient’s own immune cells to better fight cancer. The study will involve a series of treatments over a period of time, with regular monitoring to see how the cancer responds to the medication. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Participants in the study will receive the treatment through infusions and will be closely monitored by healthcare professionals. The study aims to understand the effectiveness of Glofitamab in improving survival rates and managing the disease. It will also look at how well patients tolerate the treatment and any changes in their quality of life. The study is designed to provide valuable information that could lead to better treatment options for people with these challenging types of lymphoma.

The medications being tested are both types of targeted therapies. Mosunetuzumab is a specially designed antibody that helps the immune system recognize and attack cancer cells. Polatuzumab vedotin is a medication that combines an antibody with a substance that kills cancer cells. The study will test these medications given together through intravenous infusion or as an injection under the skin.

The study will check if this combination of medications is safe to use and how well it works in treating the lymphoma. Researchers will monitor patients for side effects and measure if the cancer responds to the treatment. The study will also look at how long any improvements last and how the medications move through the body. Additional medications may be given to help manage side effects, including prednisone, dexamethasone, paracetamol, and other supportive care medicines.